Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cellular and Molecular Biology

Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer

Summary

Most breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein, we discuss evidence for an AR agonist, not antagonist, treatment strategy.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Schematic diagram of AR-mediated inhibition of ER genomic signalling associated with anti-tumour activity.

Data availability

Not applicable.

References

  1. Somboonporn W, Davis SR, National H, Medical Research C. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev. 2004;25:374–88.

    CAS  Article  Google Scholar 

  2. McDonnell DP, Wardell SE, Chang CY, Norris JD. Next-generation endocrine therapies for breast cancer. J Clin Oncol. 2021;39:1383–8.

    Article  Google Scholar 

  3. Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Pushing estrogen receptor around in breast cancer. Endocr Relat Cancer. 2016;23:T227–T41.

    CAS  Article  Google Scholar 

  4. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003;10:292–8.

    Article  Google Scholar 

  5. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69:6131–40.

    CAS  Article  Google Scholar 

  6. Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, McNeil CM, et al. The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clin Cancer Res. 2018;24:2328–41.

    CAS  Article  Google Scholar 

  7. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 2000;14:1725–30.

    CAS  Article  Google Scholar 

  8. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16:R7.

    Article  Google Scholar 

  9. D’Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, et al. Cooperative dynamics of AR and ER activity in breast cancer. Mol Cancer Res. 2016;14:1054–67.

    Article  Google Scholar 

  10. Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, et al. A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer. Clin Cancer Res. 2020;26:6149–57.

    CAS  Article  Google Scholar 

  11. Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, et al. A phase I/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer. Clin Cancer Res. 2017;23:4046–54.

    CAS  Article  Google Scholar 

  12. Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021;27:310–20.

    CAS  Article  Google Scholar 

  13. Goldenberg IS. Testosterone propionate therapy in breast cancer. JAMA. 1964;188:1069–72.

    CAS  Article  Google Scholar 

  14. Kennedy BJ. Fluoxymesterone therapy in advanced breast cancer. N Engl J Med. 1958;259:673–5.

    CAS  Article  Google Scholar 

  15. Overmoyer B, Sanz-Altamira P, Taylor RP, Hancock ML, Dalton JT, Johnston MA, et al. Enobosarm: a targeted therapy for metastatic, androgen receptor positive, breast cancer. J Clin Oncol. 2014;32:568.

    Article  Google Scholar 

  16. Caswell-Jin JL, Curtis C. Androgen receptor agonists as breast cancer therapeutics. Nat Med. 2021;27:198–9.

    CAS  Article  Google Scholar 

  17. Michmerhuizen AR, Spratt DE, Pierce LJ, Speers CW. ARe we there yet? Understanding androgen receptor signaling in breast cancer. npj Breast Cancer. 2020;6:47.

    CAS  Article  Google Scholar 

  18. Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36:884–90.

    CAS  Article  Google Scholar 

  19. Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, et al. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Res Treat. 2021;187:155–65.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

None.

Author information

Authors and Affiliations

Authors

Contributions

TEH wrote the manuscript with critical discussions and editing from ARD and WDT.

Corresponding author

Correspondence to Wayne D. Tilley.

Ethics declarations

Funding

TEH is currently funded by a fellowship from the National Breast Cancer Foundation (IIRS-19-009). This work was supported by grants from the National Health and Medical Research Council of Australia (1130077; 1084416) and a joint Movember & National Breast Cancer Foundation Initiative Grant (MNBCF-17-012).

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Not applicable.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hickey, T.E., Dwyer, A.R. & Tilley, W.D. Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer. Br J Cancer 125, 1599–1601 (2021). https://doi.org/10.1038/s41416-021-01478-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-021-01478-8

Search

Quick links